1.Preclinical studies for pharmacokinetics and biodistribution of Ad-stTRAIL, an adenovirus delivering secretable trimeric TRAIL for gene therapy.
Chae Young KIM ; Soon Hye PARK ; Moonsup JEONG ; O Seo KWON ; Hyounmie DOH ; Su Hyung KANG ; Paul D ROBBINS ; Byong Moon KIM ; Dai Wu SEOL ; Byung Gee KIM
Experimental & Molecular Medicine 2011;43(10):580-586
Malignant glioma is the most frequent type in brain tumors. The prognosis of this tumor has not been significantly improved for the past decades and the average survival of patients is less than one year. Thus, an effective novel therapy is urgently needed. TNF-related apoptosis inducing ligand (TRAIL), known to have tumor cell-specific killing activity, has been investigated as a novel therapeutic for cancers. We have developed Ad-stTRAIL, an adenovirus delivering secretable trimeric TRAIL for gene therapy and demonstrated the potential to treat malignant gliomas. Currently, this Ad-stTRAIL gene therapy is under phase I clinical trial for malignant gliomas. Here, we report preclinical studies for Ad-stTRAIL carried out using rats. We delivered Ad-stTRAIL intracranially and determined its pharmacokinetics and biodistribution. Most Ad-stTRAIL remained in the delivered site and the relatively low number of viral genomes was detected in the opposite site of brain and cerebrospinal fluid. Similarly, only small portion of the viral particles injected was found in the blood plasma and major organs and tissues, probably due to the brain-blood barrier. Multiple administrations did not lead to accumulation of Ad-stTRAIL at the injection site and organs. Repeated delivery of Ad-stTRAIL did not show any serious side effects. Our data indicate that intracranially delivered Ad-stTRAIL is a safe approach, demonstrating the potential as a novel therapy for treating gliomas.
Adenoviridae/genetics
;
Animals
;
Blood-Brain Barrier
;
Brain/drug effects/*metabolism/pathology
;
Brain Neoplasms/genetics/metabolism/pathology/*therapy
;
Clinical Trials, Phase I as Topic
;
DNA, Viral/metabolism
;
Disease Models, Animal
;
Drug Delivery Systems
;
Drug Evaluation, Preclinical
;
*Gene Therapy
;
Glioma/genetics/metabolism/pathology/*therapy
;
Humans
;
Liver/drug effects/metabolism/pathology
;
Protein Multimerization/genetics
;
Rats
;
Spleen/drug effects/metabolism/pathology
;
TNF-Related Apoptosis-Inducing Ligand/genetics/*pharmacokinetics
2.Preclinical studies for pharmacokinetics and biodistribution of Ad-stTRAIL, an adenovirus delivering secretable trimeric TRAIL for gene therapy.
Chae Young KIM ; Soon Hye PARK ; Moonsup JEONG ; O Seo KWON ; Hyounmie DOH ; Su Hyung KANG ; Paul D ROBBINS ; Byong Moon KIM ; Dai Wu SEOL ; Byung Gee KIM
Experimental & Molecular Medicine 2011;43(10):580-586
Malignant glioma is the most frequent type in brain tumors. The prognosis of this tumor has not been significantly improved for the past decades and the average survival of patients is less than one year. Thus, an effective novel therapy is urgently needed. TNF-related apoptosis inducing ligand (TRAIL), known to have tumor cell-specific killing activity, has been investigated as a novel therapeutic for cancers. We have developed Ad-stTRAIL, an adenovirus delivering secretable trimeric TRAIL for gene therapy and demonstrated the potential to treat malignant gliomas. Currently, this Ad-stTRAIL gene therapy is under phase I clinical trial for malignant gliomas. Here, we report preclinical studies for Ad-stTRAIL carried out using rats. We delivered Ad-stTRAIL intracranially and determined its pharmacokinetics and biodistribution. Most Ad-stTRAIL remained in the delivered site and the relatively low number of viral genomes was detected in the opposite site of brain and cerebrospinal fluid. Similarly, only small portion of the viral particles injected was found in the blood plasma and major organs and tissues, probably due to the brain-blood barrier. Multiple administrations did not lead to accumulation of Ad-stTRAIL at the injection site and organs. Repeated delivery of Ad-stTRAIL did not show any serious side effects. Our data indicate that intracranially delivered Ad-stTRAIL is a safe approach, demonstrating the potential as a novel therapy for treating gliomas.
Adenoviridae/genetics
;
Animals
;
Blood-Brain Barrier
;
Brain/drug effects/*metabolism/pathology
;
Brain Neoplasms/genetics/metabolism/pathology/*therapy
;
Clinical Trials, Phase I as Topic
;
DNA, Viral/metabolism
;
Disease Models, Animal
;
Drug Delivery Systems
;
Drug Evaluation, Preclinical
;
*Gene Therapy
;
Glioma/genetics/metabolism/pathology/*therapy
;
Humans
;
Liver/drug effects/metabolism/pathology
;
Protein Multimerization/genetics
;
Rats
;
Spleen/drug effects/metabolism/pathology
;
TNF-Related Apoptosis-Inducing Ligand/genetics/*pharmacokinetics
3.Adenovirus mediated IL-24 gene expression inhibits growth of human glioma cell in vitro.
Yunbo SHAN ; Weihua SHENG ; Yufeng XIE ; Tielian LIU ; Yingying JING ; Zhiqing HU ; Jicheng YANG
Chinese Journal of Biotechnology 2009;25(2):279-286
To investigate the inhibitory effect and anti-cancer mechanism of adenovirus mediated IL-24 gene expression on the human U251 glioma cell. U251 glioma cells were infected with Ad-IL-24 at various multiplicity of infection (MOIs). Cell proliferation was determined by MTT assay. Cell apoptosis was detected by flow cytometry and Hochest staining. The transcription of apoptosis-related genes was analyzed by reverse transcription-PCR (RT-PCR), and the expression of Cleaved Caspase-3 was analyzed by Western blotting. The result showed that the growth of U251 glioma cells was significantly inhibited by Ad-IL-24 at the MOI of 100. The apoptotic rate of U251 glioma cells was 42% 72 h after infection with Ad-IL-24. Four days after infection, the growth of the U251 glioma cells was inhibited to 50%. RT-PCR showed that Ad-IL-24 not only up-regulated expression of bax/bcl-2, ICE, C-myc, p53 and down-regulated the expression of HIF-1alpha, but also enhanced Caspase-3 activation, eventually resulting apoptosis. Taken together, these results suggest that infection of U251 glioma cells with Ad-IL-24 can inhibit growth and induce apoptosis significantly by the regulation of apoptosis-related genes.
Adenoviridae
;
genetics
;
metabolism
;
Apoptosis
;
Brain Neoplasms
;
genetics
;
pathology
;
Cell Proliferation
;
drug effects
;
Genetic Therapy
;
Glioma
;
genetics
;
pathology
;
Humans
;
Interleukins
;
genetics
;
metabolism
;
Recombination, Genetic
;
Tumor Cells, Cultured
4.Hypermethylation of testis derived transcript gene promoter significantly correlates with worse outcomes in glioblastoma patients.
Li-jia WANG ; Yu BAI ; Zhao-shi BAO ; Yan CHEN ; Zhuo-hong YAN ; Wei ZHANG ; Quan-geng ZHANG
Chinese Medical Journal 2013;126(11):2062-2066
BACKGROUNDGlioblastoma is the most common and lethal cancer of the central nervous system. Global genomic hypomethylation and some CpG island hypermethylation are common hallmarks of these malignancies, but the effects of these methylation abnormalities on glioblastomas are still largely unclear. Methylation of the O6-methylguanine-DNA methyltransferase promoter is currently an only confirmed molecular predictor of better outcome in temozolomide treatment. To better understand the relationship between CpG island methylation status and patient outcome, this study launched DNA methylation profiles for thirty-three primary glioblastomas (pGBMs) and nine secondary glioblastomas (sGBMs) with the expectation to identify valuable prognostic and therapeutic targets.
METHODSWe evaluated the methylation status of testis derived transcript (TES) gene promoter by microarray analysis of glioblastomas and the prognostic value for TES methylation in the clinical outcome of pGBM patients. Significance analysis of microarrays was used for genes significantly differently methylated between 33 pGBM and nine sGBM. Survival curves were calculated according to the Kaplan-Meier method, and differences between curves were assessed using the log-rank test. Then, we treated glioblastoma cell lines (U87 and U251) with 5-aza-2-deoxycytidines (5-aza-dC) and detected cell biological behaviors.
RESULTSMicroarray data analysis identified TES promoter was hypermethylated in pGBMs compared with sGBMs (P < 0.05). Survival curves from the Kaplan-Meier method analysis revealed that the patients with TES hypermethylation had a short overall survival (P < 0.05). This abnormality is also confirmed in glioblastoma cell lines (U87 and U251). Treating these cells with 5-aza-dC released TES protein expression resulted in significant inhibition of cell growth (P = 0.013).
CONCLUSIONSHypermethylation of TES gene promoter highly correlated with worse outcome in pGBM patients. TES might represent a valuable prognostic marker for glioblastoma.
Azacitidine ; analogs & derivatives ; pharmacology ; Brain Neoplasms ; drug therapy ; genetics ; pathology ; Cell Line, Tumor ; Cell Proliferation ; drug effects ; Cytoskeletal Proteins ; genetics ; DNA Methylation ; Glioblastoma ; drug therapy ; genetics ; pathology ; Humans ; LIM Domain Proteins ; genetics ; Promoter Regions, Genetic ; Treatment Outcome
5.Intracranial involvement in newly diagnosed multiple myeloma with TP53 deletion: Two case reports.
Shuang QU ; Lisheng LIAO ; Ying XIE ; Zhihai ZHENG ; Biyun CHEN
Journal of Central South University(Medical Sciences) 2018;43(11):1272-1275
We report two rare cases of multiple myeloma (MM) with dural intracranial disease and TP53 deletion. The two patients presented with skull lytic lesion and dural involvement of myeloma. The association between intracranial involvement in MM and TP53 deletion has not been determined. The two patients received bortezomib-based intensive induction and got good response, just as that reported in literature. MM presenting with dural intracranial disease and TP53 deletion at diagnosis is associated with poor outcome. Multi-drug regime containing bortezomib followed by autologous or allogeneic stem cell transportation would improve the prognosis.
Antineoplastic Agents
;
therapeutic use
;
Antineoplastic Combined Chemotherapy Protocols
;
Bortezomib
;
therapeutic use
;
Brain Neoplasms
;
drug therapy
;
genetics
;
pathology
;
Gene Deletion
;
Humans
;
Multiple Myeloma
;
drug therapy
;
genetics
;
pathology
;
Prognosis
;
Treatment Outcome
;
Tumor Suppressor Protein p53
;
genetics
6.DNMT1 mediates chemosensitivity by reducing methylation of miRNA-20a promoter in glioma cells.
Daoyang ZHOU ; Yingfeng WAN ; Dajiang XIE ; Yirong WANG ; Junhua WEI ; Qingfeng YAN ; Peng LU ; Lianjie MO ; Jixi XIE ; Shuxu YANG ; Xuchen QI
Experimental & Molecular Medicine 2015;47(9):e182-
Although methyltransferase has been recognized as a major element that governs the epigenetic regulation of the genome during temozolomide (TMZ) chemotherapy in glioblastoma multiforme (GBM) patients, its regulatory effect on glioblastoma chemoresistance has not been well defined. This study investigated whether DNA methyltransferase (DNMT) expression was associated with TMZ sensitivity in glioma cells and elucidated the underlying mechanism. DNMT expression was analyzed by western blotting. miR-20a promoter methylation was evaluated by methylation-specific PCR. Cell viability and apoptosis were assessed using the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) and TdT-mediated dUTP-biotin nick end labeling assays, respectively. The results showed that compared with parental U251 cells, DNMT1 expression was downregulated, miR-20a promoter methylation was attenuated and miR-20a levels were elevated in TMZ-resistant U251 cells. Methyltransferase inhibition by 5-aza-2\'-deoxycytidine treatment reduced TMZ sensitivity in U251 cells. In U251/TM cells, DNMT1 expression was negatively correlated with miR-20a expression and positively correlated with TMZ sensitivity and leucine-rich repeats and immunoglobulin-like domains 1 expression; these effects were reversed by changes in miR-20a expression. DNMT1 overexpression induced an increase in U251/TM cell apoptosis that was inhibited by the miR-20a mimic, whereas DNMT1 silencing attenuated U251/TM cell apoptosis in a manner that was abrogated by miR-20a inhibitor treatment. Tumor growth of the U251/TM xenograft was inhibited by pcDNA-DNMT1 pretreatment and boosted by DNMT1-small hairpin RNA pretreatment. In summary, DNMT1 mediated chemosensitivity by reducing methylation of the microRNA-20a promoter in glioma cells.
Animals
;
Antineoplastic Agents, Alkylating/*pharmacology/therapeutic use
;
Apoptosis/drug effects
;
Brain/drug effects/metabolism/pathology
;
Brain Neoplasms/drug therapy/*genetics/pathology
;
DNA (Cytosine-5-)-Methyltransferase/antagonists & inhibitors/*genetics/metabolism
;
DNA Methylation
;
Dacarbazine/*analogs & derivatives/pharmacology/therapeutic use
;
Drug Resistance, Neoplasm
;
Female
;
Gene Expression Regulation, Neoplastic
;
Glioma/drug therapy/*genetics/pathology
;
Humans
;
Mice, Inbred C57BL
;
MicroRNAs/*genetics
;
Promoter Regions, Genetic
7.Prognostic Analysis of EGFR-TKIs Combined with Gamma Knife in EGFR-mutant Lung Adenocarcinoma with Brain Metastasis.
Limin CHEN ; Mengjiao FU ; Jianya ZHOU ; Yinan YAO ; Jianying ZHOU
Chinese Journal of Lung Cancer 2019;22(5):312-318
BACKGROUND:
Advanced epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma had a high overall incidence of brain metastasis during the full course, and local brain radiotherapy combined with systemic targeted therapy may be a better strategy. This study aimed to identify the prognostic factors of EGFR-mutant brain-metastatic lung adenocarcinoma patients who received EGFR-tyrosine kinase inhibitors (EGFR-TKIs) in combination with gamma knife radiosurgery.
METHODS:
Retrospective analysis of EGFR-mutant lung adenocarcinoma patients with brain metastases which developed at initial diagnosis or during EGFR-TKIs treatment period were performed. Intracranial progression free survival (PFS) was statistically analyzed between different subgroups to find out the prognostic factors including gender, age, smoking history, extracranial metastasis, EGFR mutation type, size and number of intracranial lesions, carcino-embryonic antigen (CEA) level, lung-molGPA score and so on.
RESULTS:
A total of 74 EGFR-mutant brain-metastatic lung adenocarcinoma patients were enrolled in this study, with median intracranial PFS of 14.7 months. One-year intracranial-progression-free rate was 58.5%, and two-year rate was 22.2%. Univariate survival analysis showed that patients with lower CEA level at initial diagnosis (<10 ng/L)(16.9 months vs 12.6 months, P=0.012) and smaller intracranial lesions (<2 cm)(15.4 months vs 10.8 months, P=0.021) and higher lung-molGPA score (>3)(15 months vs 12.6 months, P=0.041) were prone to have a superior intracranial PFS. Multivariate analysis showed that CEA≥10 ng/mL and intracranial lesion≥2 cm were the independent risk factors of intracranial PFS.
CONCLUSIONS
EGFR-TKIs in combination with gamma knife radiosurgery was an efficient treatment option to control the cranial tumor lesion. CEA≥10 μg/L at initial diagnosis and intracranial lesion≥2 cm were the risk factors of EGFR-mutant brain-metastatic lung adenocarcinoma patients receiving EGFR-TKIs in combination with gamma knife radiosurgery.
Adenocarcinoma of Lung
;
drug therapy
;
pathology
;
radiotherapy
;
therapy
;
Adult
;
Aged
;
Brain Neoplasms
;
secondary
;
Combined Modality Therapy
;
ErbB Receptors
;
antagonists & inhibitors
;
genetics
;
Female
;
Humans
;
Male
;
Middle Aged
;
Mutation
;
Prognosis
;
Protein Kinase Inhibitors
;
pharmacology
;
therapeutic use
;
Radiosurgery
;
Retrospective Studies
8.Interpretation of the updates of NCCN 2017 version 1.0 guideline for colorectal cancer.
Chinese Journal of Gastrointestinal Surgery 2017;20(1):28-33
The NCCN has recently released its 2017 version 1.0 guideline for colorectal cancer. There are several updates from this new version guideline which are believed to change the current clinical practice. Update one, low-dose aspirin is recommended for patients with colorectal cancer after colectomy for secondary chemoprevention. Update two, biological agents are removed from the neoadjuvant treatment regimen for resectable metastatic colorectal cancer (mCRC). This update is based on lack of evidence to support benefits of biological agents including bevacizumab and cetuximab in the neoadjuvant setting. Both technical criteria and prognostic information should be considered for decision-making. Currently biological agents may not be excluded from the neoadjuvant setting for patients with resectable but poor prognostic disease. Update three, panitumumab and cetuximab combination therapy is only recommended for left-sided tumors in the first line therapy. The location of the primary tumor can be both prognostic and predictive in response to EGFR inhibitors in metastatic colorectal cancer. Cetuximab and panitumumab confer little benefit to patients with metastatic colorectal cancer in the primary tumor originated on the right side. On the other hand, EGFR inhibitors provide significant benefit compared with bevacizumab-containing therapy or chemotherapy alone for patients with left primary tumor. Update four, PD-1 immune checkpoint inhibitors including pembrolizumab or nivolumab are recommended as treatment options in patients with metastatic deficient mismatch repair (dMMR) colorectal cancer in second- or third-line therapy. dMMR tumors contain thousands of mutations, which can encode mutant proteins with the potential to be recognized and targeted by the immune system. It has therefore been hypothesized that dMMR tumors may be sensitive to PD-1 inhibitors.
Antibodies, Monoclonal
;
pharmacology
;
therapeutic use
;
Antibodies, Monoclonal, Humanized
;
therapeutic use
;
Antineoplastic Agents
;
therapeutic use
;
Antineoplastic Combined Chemotherapy Protocols
;
therapeutic use
;
Aspirin
;
administration & dosage
;
therapeutic use
;
Bevacizumab
;
therapeutic use
;
Biological Products
;
therapeutic use
;
Brain Neoplasms
;
drug therapy
;
genetics
;
Cetuximab
;
therapeutic use
;
Clinical Decision-Making
;
methods
;
Colorectal Neoplasms
;
drug therapy
;
genetics
;
pathology
;
prevention & control
;
therapy
;
Contraindications
;
Humans
;
Mutation
;
physiology
;
Neoadjuvant Therapy
;
standards
;
Neoplasm Metastasis
;
drug therapy
;
Neoplastic Syndromes, Hereditary
;
drug therapy
;
genetics
;
Practice Guidelines as Topic
;
Prognosis
;
Secondary Prevention
;
methods
;
standards
9.Recent advances in the role of toll-like receptors and TLR agonists in immunotherapy for human glioma.
Shuanglin DENG ; Shan ZHU ; Yuan QIAO ; Yong-Jun LIU ; Wei CHEN ; Gang ZHAO ; Jingtao CHEN
Protein & Cell 2014;5(12):899-911
Gliomas are extremely aggressive brain tumors with a very poor prognosis. One of the more promising strategies for the treatment of human gliomas is targeted immunotherapy where antigens that are unique to the tumors are exploited to generate vaccines. The approach, however, is complicated by the fact that human gliomas escape immune surveillance by creating an immune suppressed microenvironment. In order to oppose the glioma imposed immune suppression, molecules and pathways involved in immune cell maturation, expansion, and migration are under intensive clinical investigation as adjuvant therapy. Toll-like receptors (TLRs) mediate many of these functions in immune cell types, and TLR agonists, thus, are currently primary candidate molecules to be used as important adjuvants in a variety of cancers. In animal models for glioma, TLR agonists have exhibited antitumor properties by facilitating antigen presentation and stimulating innate and adaptive immunity. In clinical trials, several TLR agonists have achieved survival benefit, and many more trials are recruiting or ongoing. However, a second complicating factor is that TLRs are also expressed on cancer cells where they can participate instead in a variety of tumor promoting activities including cell growth, proliferation, invasion, migration, and even stem cell maintenance. TLR agonists can, therefore, possibly play dual roles in tumor biology. Here, how TLRs and TLR agonists function in glioma biology and in anti-glioma therapies is summarized in an effort to provide a current picture of the sophisticated relationship of glioma with the immune system and the implications for immunotherapy.
Animals
;
Antigens, Neoplasm
;
chemistry
;
immunology
;
Antineoplastic Agents
;
chemistry
;
immunology
;
therapeutic use
;
Brain Neoplasms
;
genetics
;
immunology
;
pathology
;
therapy
;
Chemotherapy, Adjuvant
;
Clinical Trials as Topic
;
Disease Models, Animal
;
Gene Expression Regulation, Neoplastic
;
drug effects
;
immunology
;
Glioma
;
genetics
;
immunology
;
pathology
;
therapy
;
Humans
;
Immunotherapy
;
methods
;
Signal Transduction
;
Toll-Like Receptors
;
agonists
;
genetics
;
immunology
10.Prognostic significance of ERCC1 mRNA expression in patients with non-small cell lung cancer receiving platinum-based chemotherapy.
Xiao-ping QIAN ; Bao-rui LIU ; Mei-qi SHI ; Xin-zi LIU ; Wen-jing HU ; Zheng-yun ZOU ; Jia WEI
Chinese Journal of Oncology 2009;31(1):33-37
OBJECTIVETo investigate the correlation of the mRNA expression level of excision repair cross-complementing group 1 (ERCC1) gene with clinicopathological parameters and clinical outcome in patients with non-small cell lung cancer (NSCLC) receiving platinum-based chemotherapy.
METHODSThe mRNA expression of ERCC1 in formalin-fixed paraffin-embedded primary tumor specimens was measured by real-time quantitative reverse transcriptase polymerase chain reaction. The association between ERCC1 expression levels and clinicopathological parameters in NSCLC patients was analyzed.
RESULTSThe median value of ERCC1 mRNA expression level compared with beta-actin in tumor specimens of 61 NSCLC patients was 0.48. There was no correlation between ERCC1 expression and clinicopathological parameters. Patients with low expression of ERCC1 mRNA (less than 0.35, 0.28, respectively) had a significantly longer median time to progression (TTP) (14.3 vs. 8.0 months, P = 0.028) and overall survival (OS) (28.4 vs. 12.9 months, P = 0.0064) than those with high expression. Multivariate analysis showed that a low ERCC1 mRNA expression was an independent factor for OS.
CONCLUSIONOur findings suggest that intratumoral ERCC1 mRNA expression level, although is uncorrelated with clinicopathological parameters, is an independent predictive marker for survival of the patients with NSCLC receiving platinum-based chemotherapy, and may provide critical information for personalized chemotherapy.
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols ; therapeutic use ; Bone Neoplasms ; secondary ; Brain Neoplasms ; secondary ; Carcinoma, Non-Small-Cell Lung ; drug therapy ; metabolism ; pathology ; secondary ; Cisplatin ; administration & dosage ; DNA-Binding Proteins ; genetics ; metabolism ; Disease-Free Survival ; Endonucleases ; genetics ; metabolism ; Female ; Follow-Up Studies ; Humans ; Lung Neoplasms ; drug therapy ; metabolism ; pathology ; Lymphatic Metastasis ; Male ; Middle Aged ; Neoplasm Staging ; Paraffin Embedding ; Platinum ; administration & dosage ; Proportional Hazards Models ; RNA, Messenger ; metabolism ; Survival Rate